Design, synthesis and biological evaluation of curcumin analogues as novel LSD1 inhibitors
作者:Jiming Wang、Xiangyu Zhang、Jiangkun Yan、Wei Li、Qinwen Jiang、Xinran Wang、Dongmei Zhao、Maosheng Cheng
DOI:10.1016/j.bmcl.2019.126683
日期:2019.12
downregulating its expression inhibits cancer-cell development, and thus, it is an attractive molecular target for the development of novel cancer therapeutics. In this study, we worked on the structural optimization of natural products and identified 30 novel LSD1 inhibitors. Utilizing a structure-based drug design strategy, we designed and synthesized a series of curcumin analogues that were shown to be
组蛋白赖氨酸特异性脱甲基酶1(LSD1)是第一个发现的组蛋白脱甲基酶。灭活LSD1或下调LSD1的表达会抑制癌细胞的发育,因此,它是开发新型癌症治疗剂的有吸引力的分子靶标。在这项研究中,我们致力于天然产物的结构优化,并确定了30种新型LSD1抑制剂。利用基于结构的药物设计策略,我们设计并合成了一系列姜黄素类似物,这些酶在酶法测定中被证明是有效的LSD1抑制剂。化合物WB07表现出最强的LSD1抑制活性,IC 50值为0.8μM。此外,WA20的IC 50对A549细胞显示出抑癌作用值为4.4μM。还进行了分子对接模拟,结果表明该抑制剂与位于Asp555和Asp556关键残基周围的蛋白质活性位点结合。这些发现表明,化合物WA20和WB07是第一种具有显着的A549抑制活性的基于姜黄素类似物的LSD1抑制剂,为LSD1抑制剂的开发提供了新颖的支架。